influenza A (H1N1) vaccine (GSK)

The influenza A (H1N1) vaccine is a monovalent vaccine developed to provide active immunization against the A/H1N1 strain of the influenza virus, specifically the pandemic strain that emerged in 2009 (A/California/07/2009). These vaccines were produced using several technologies, including inactivated split-virion, surface antigen, and live-attenuated platforms. The vaccine works by presenting viral antigens, primarily hemagglutinin (HA) and neuraminidase (NA), to the immune system to induce the production of neutralizing antibodies. These antibodies prevent viral attachment and entry into host cells. During the 2009 pandemic, various formulations were used, some containing adjuvants like AS03 or MF59 to enhance the immune response. Clinical research, such as the ESRA study conducted by the Academisch Medisch Centrum, has specifically evaluated the safety and immunogenicity of these vaccines in patients with autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, demonstrating that the vaccine is generally safe and effective in these populations despite the use of immunosuppressive therapies.

Brand names

PandemrixFocetriaCelvapanPanenzaArepanrix

Other names

A/H1N1 Influenza VaccineH1N1 vaccineH-1N1 vaccineH 1N1 vaccinepandemic H1N1 vaccinemonovalent influenza A (H1N1) vaccine2009 H1N1 vaccine